Latest news with #GlaxoSmithKline
South China Morning Post
2 days ago
- Business
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRS-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The GSK corporate flag next to a Chinese national flag outside its office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
South China Morning Post
2 days ago
- Business
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. Advertisement The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their product portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The corporate flag of GlaxoSmithKline (GSK) next to a Chinese national flag outside a GlaxoSmithKline office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. Advertisement 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
Reuters
2 days ago
- Business
- Reuters
Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal
HONG KONG, July 28 (Reuters) - China's Jiangsu Hengrui Pharmaceuticals ( opens new tab said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 other programmes to GlaxoSmithKline Intellectual Property (GSK) for $500 million upfront. The Chinese pharma group said, opens new tab it could earn up to $12 billion in milestone payments if all options are exercised and targets are met. HRS-9821 is being developed to treat chronic obstructive pulmonary disease (COPD), while the other projects are in early development across areas such as oncology, respiratory, immunology, and inflammation. Shanghai shares of Jiangsu Hengrui climbed 6.6% and its Hong Kong-listed stock jumped 8.5%, outperforming the blue-chip CSI 300 Index's (.CSI300), opens new tab 0.1% slip and the Hang Seng Index's (.HSI), opens new tab 0.3% gain.
Business Upturn
6 days ago
- Health
- Business Upturn
Rheumatologists Eye AbbVie's Rinvoq, Roche/Genentech's Gazyva, and Bristol Myers Squibb's Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports
EXTON, PA, July 23, 2025 (GLOBE NEWSWIRE) — Biologic use in systemic lupus erythematosus (SLE) is steadily rising, with U.S. rheumatologists now treating close to 40% of their moderate-to-severe patients with biologics. Most expect this number to increase as comfort with existing therapies grows and new treatment options become available. GlaxoSmithKline's Benlysta continues to lead the SLE biologic market, though AstraZeneca's Saphnelo is gaining share—especially in patients with cutaneous manifestations. The anticipated launch of a subcutaneous formulation is expected to further accelerate uptake, with rheumatologists projecting notable growth following approval. Despite these gains, most prescribers continue to highlight substantial gaps in care. Fatigue remains the top unmet symptom across the SLE population, and long-term steroid use is still common, despite guideline recommendations and widespread prescriber agreement on their risks. Over three-quarters of rheumatologists agree that currently available options do not adequately support treatment goals in all patient segments—particularly among those with refractory disease or renal involvement. 'For me, the dream is a therapeutic regimen with no corticosteroids,' one physician emphasized. 'That's still the biggest frustration—having to use steroids when flares hit, even if we taper fast.' Others underscored a broader desire for therapies that achieve true remission. 'We need a drug that doesn't just suppress symptoms but can lead to remission—and ideally, drug-free remission.' Interest in the SLE pipeline is strong, particularly for AbbVie's Rinvoq (upadacitinib), Bristol Myers Squibb's Sotyktu (deucravacitinib), and Roche/Genentech's Gazyva (obinutuzumab). Rheumatologists believe these therapies could meaningfully expand the treatment landscape. Both Rinvoq and Sotyktu are viewed as attractive oral options in a market dominated by infusions and injectables, with strong cross-indication familiarity helping drive prescriber confidence. Gazyva, already supported by positive data in lupus nephritis (LN), is expected to play a key role in patients with renal involvement if approved. Litifilimab (developed by Biogen) is also on rheumatologists' radar. The therapy's novel mechanism of action and convenient monthly subcutaneous dosing contribute to high interest. Most prescribers report they would consider it for a sizable portion of their SLE population, especially those who prefer injectables over oral agents or infusions. Similarly, ianalumab (Novartis) and CD40 ligand inhibitors are generating early enthusiasm as potential next-generation biologics, particularly in patients who have cycled through multiple treatment lines. When evaluating emerging therapies, most rheumatologists define a meaningful advance over placebo as at least a 20–35% difference in response, depending on the endpoint used. Based on available Phase 2 trial data, litifilimab stands out for surpassing that threshold in SRI-4. Looking ahead to potential head-to-head clinical trials, Benlysta is viewed as the most appropriate active comparator by a wide margin, selected by over 80% of rheumatologists, far outpacing preferences for Saphnelo or off-label rituximab. These benchmarks highlight how prescribers are contextualizing new agents within existing efficacy standards and where they see real differentiation emerging. Looking further ahead, CAR T-cell therapy represents one of the most potentially disruptive innovations in SLE. While still in early clinical development, more than half of rheumatologists expect this modality to play a leading or definite role in future treatment. On average, prescribers estimate that up to one in six of their current patients could ultimately be candidates for a cell-based therapy. Among those expressing interest, the greatest perceived value lies in its potential to induce sustained or even drug-free remission—something current therapies rarely, if ever, achieve. Prescribing behavior is also shifting in preparation for these advancements. Most rheumatologists now report initiating biologics earlier in the disease course, particularly in patients who fail to reach treatment goals within the first few months of standard therapy. Rather than sequentially adding a conventional DMARD such as azathioprine to hydroxychloroquine (HCQ), many are moving directly to biologics given the severity of lupus and the cumulative damage associated with long-term steroid exposure. Biologics such as Benlysta and Saphnelo are increasingly being layered onto conventional regimens after a short trial of HCQ and corticosteroids, reflecting a more aggressive, target-driven approach to management. As these pipeline therapies advance toward potential approval, Spherix will continue monitoring how clinical perceptions and prescribing behaviors evolve. A pipeline refresh study launching this fall will provide updated insights on rheumatologist sentiment, expected adoption trajectories, and market preparedness as the next wave of SLE innovation approaches. In addition, Spherix will be publishing a companion study, Special Topix™: Cell Therapy in Rheumatology later this summer, focused specifically on the evolving role of cell therapy in rheumatology, including physician awareness, expectations, and potential barriers to adoption. Special Topix™ is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
CairoScene
7 days ago
- Business
- CairoScene
Regional Vaccine Hub Launched at Khalifa Economic Zones
Developed with GlaxoSmithKline and operated by Rafed, the facility will handle more than 20 vaccines for adults and children with smart cold-chain tech and international reach via Etihad PharmaLife. Jul 22, 2025 A new vaccine distribution hub is now operational at Khalifa Economic Zones Abu Dhabi (KEZAD), expanding the emirate's role in global healthcare logistics. Developed with GlaxoSmithKline and operated by Rafed, the facility will handle more than 20 vaccines for adults and children. Featuring advanced cold-chain systems designed to ensure vaccines are stored and transported under tightly controlled conditions, the hub is connected to Etihad Cargo's PharmaLife network, enabling time-sensitive pharmaceutical shipments to over 100 global destinations. The project builds on partnerships formed during the COVID-19 pandemic. In 2021, Abu Dhabi was the first city to receive Sotrovimab, a monoclonal antibody developed by GlaxoSmithKline. The treatment was administered to more than 23,000 high-risk patients, setting a precedent for future collaboration in pharmaceutical logistics. The facility joins a broader infrastructure push within Abu Dhabi's healthcare sector. During the pandemic, the emirate's Hope Consortium managed one of the world's largest vaccine storage hubs in Khalifa Industrial Zone, distributing millions of doses globally.
